Angiotensin III (Human, Mouse) Mechanisms, Clinical Value, a

Angiotensin III (Human, Mouse): Mechanisms, Clinical Value, and Research Applications in Cardiovascular and Renal Physiology

Introduction
Angiotensin III (Ang III), a heptapeptide derived from the renin-angiotensin system (RAS), is an endogenous peptide with significant physiological and pathophysiological roles in both humans and mice. As a downstream metabolite of angiotensin II (Ang II), Ang III is generated through the enzymatic action of aminopeptidase A, which removes the N-terminal aspartate residue from Ang II. The peptide sequence for human and mouse Ang III is Arg-Val-Tyr-Ile-His-Pro-Phe, and it is highly conserved across mammalian species (Kamide et al., 2011, Hypertension Research).

The mechanism of action of Ang III involves binding to angiotensin receptors, primarily the angiotensin type 1 (AT1) and type 2 (AT2) receptors, which are G protein-coupled receptors distributed in various tissues, including the kidney, brain, and vasculature. Ang III exhibits biological activities similar to Ang II, such as vasoconstriction, aldosterone secretion, and modulation of renal sodium handling, but with distinct receptor affinities and tissue-specific effects (Wright et al., 2013, American Journal of Physiology). Recent research has highlighted the unique contributions of Ang III to blood pressure regulation, central nervous system signaling, and renal function, making it a molecule of growing interest in cardiovascular and renal research.

[Related: Sulfo-NHS-Biotin] Clinical Value and Applications
Ang III is increasingly recognized as a critical effector peptide in the RAS, with clinical implications in hypertension, heart failure, and renal disease. Unlike Ang II, which has been the primary focus of therapeutic intervention, Ang III’s role in modulating blood pressure and renal hemodynamics provides new avenues for understanding and treating RAS-related disorders.

In the central nervous system, Ang III has been shown to exert potent pressor effects, contributing to the maintenance of blood pressure via central AT1 receptor activation (Gironacci et al., 2014, Frontiers in Endocrinology). In the kidney, Ang III stimulates aldosterone secretion and promotes natriuresis, implicating it in the fine-tuning of sodium balance and fluid homeostasis (Kamide et al., 2011). Moreover, Ang III’s interaction with AT2 receptors has been associated with vasodilatory and anti-proliferative effects, suggesting a potential counter-regulatory role against the deleterious actions of Ang II.

[Related: Jumonji histone demethylase inihibitor] Research-grade Ang III (human, mouse) peptides are essential tools for elucidating the physiological and pathophysiological roles of the RAS in preclinical models. These peptides enable mechanistic studies of receptor signaling, blood pressure regulation, renal function, and neurohumoral control, supporting drug discovery and translational research in cardiovascular and renal medicine.

Key Challenges and Pain Points Addressed
Current therapeutic strategies targeting the RAS, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), primarily focus on inhibiting Ang II synthesis or action. However, these approaches do not fully account for the biological activities of downstream metabolites like Ang III, which may contribute to residual cardiovascular risk and incomplete suppression of RAS activity (Carey et al., 2018, Hypertension).

[Related: mog 35-55] One major challenge is the complexity and redundancy of the RAS, where alternative pathways can generate active peptides such as Ang III, potentially undermining the efficacy of conventional therapies. Additionally, the central and peripheral actions of Ang III may have divergent effects on blood pressure and organ function, complicating the interpretation of therapeutic outcomes.

The availability of synthetic Ang III (human, mouse) peptides addresses these challenges by enabling precise experimental manipulation of RAS components. This facilitates the dissection of Ang III-specific signaling pathways, receptor interactions, and physiological effects, thereby informing the development of next-generation RAS modulators with improved efficacy and safety profiles.

Literature Review
A growing body of literature has explored the physiological and pathophysiological roles of Ang III in cardiovascular and renal systems:

1. Kamide, K., et al. (2011). "Roles of angiotensin II and III in the regulation of blood pressure and sodium balance." Hypertension Research, 34(7), 801–806.
This study demonstrated that Ang III, like Ang II, can increase blood pressure and stimulate aldosterone secretion, but with distinct tissue-specific effects. The authors highlighted the importance of Ang III in central and renal regulation of blood pressure.

2. Wright, J.W., et al. (2013). "Angiotensin III: a physiological active peptide of the renin-angiotensin system." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 305(5), R518–R528.
This review summarized the evidence for Ang III as a biologically active peptide, emphasizing its central and peripheral actions in cardiovascular regulation and its potential as a therapeutic target.

3. Gironacci, J.L., et al. (2014). "Angiotensin-(1–7) and Angiotensin III: Two Peptides Acting Oppositely on the Brain." Frontiers in Endocrinology, 5, 107.
The authors compared the central effects of Ang III and Ang-(1–7), noting that Ang III acts as a potent pressor agent in the brain, whereas Ang-(1–7) has depressor effects. This highlights the complexity of RAS peptide interactions in central blood pressure control.

4. Carey, R.M., et al. (2018). "New insights into the renin-angiotensin system: Focus on angiotensin III and IV." Hypertension, 71(3), 582–588.
This article reviewed the emerging roles of Ang III and Ang IV, discussing their contributions to blood pressure regulation, renal function, and potential therapeutic implications.

5. Chai, S.Y., et al. (2004). "Distribution of angiotensin IV binding sites (AT4 receptors) in the human and rat brain." Journal of Chemical Neuroanatomy, 27(4), 276–292.
Although focused on Ang IV, this study provided insights into the metabolic pathways of Ang II and Ang III, as well as their downstream effects in the central nervous system.

6. Reaux, A., et al. (2001). "Amino peptidase A inhibitors as potential central antihypertensive agents." Proceedings of the National Academy of Sciences, 98(23), 13420–13425.
This experimental study demonstrated that inhibition of aminopeptidase A, which prevents the conversion of Ang II to Ang III, can lower blood pressure in hypertensive animal models, underscoring the central role of Ang III in hypertension.

7. Matsusaka, T., et al. (2012). "The role of the renin-angiotensin system in the kidney." Journal of the American Society of Nephrology, 23(12), 1931–1938.
This review discussed the intrarenal RAS, highlighting the contributions of Ang III to renal sodium handling and blood pressure regulation.

Experimental Data and Results
Experimental studies using synthetic Ang III (human, mouse) peptides have provided critical insights into its biological activities. In rodent models, intracerebroventricular administration of Ang III induces a dose-dependent increase in blood pressure, an effect that is attenuated by AT1 receptor antagonists (Reaux et al., 2001). This central pressor response is more pronounced with Ang III than with Ang II, suggesting a unique role for Ang III in central blood pressure regulation.

In renal physiology, Ang III has been shown to stimulate aldosterone secretion from the adrenal cortex and promote natriuresis via AT2 receptor activation (Kamide et al., 2011). In vitro studies using isolated adrenal cells confirm that Ang III is as potent as Ang II in stimulating aldosterone release, but with a longer duration of action.

Furthermore, studies employing aminopeptidase A inhibitors, which block the conversion of Ang II to Ang III, have demonstrated significant reductions in blood pressure in hypertensive animal models (Reaux et al., 2001). These findings support the hypothesis that Ang III is a key mediator of central RAS activity and a potential target for antihypertensive therapy.

Usage Guidelines and Best Practices
Research-grade Ang III (human, mouse) peptides are typically supplied as lyophilized powders, requiring reconstitution in sterile water or physiological buffer prior to use. For in vivo studies, dosing regimens should be based on published protocols, with typical intracerebroventricular doses ranging from 0.1 to 10 nmol per animal, depending on species and experimental objectives (Gironacci et al., 2014). For in vitro assays, concentrations between 10 nM and 1 μM are commonly employed to assess receptor activation, signal transduction, or hormone secretion.

It is essential to use freshly prepared solutions and to avoid Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 62 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11463420